The latest price target for Quince Therapeutics (NASDAQ:QNCX) was reported by Brookline Capital on December 18, 2024. The analyst firm set a price target for $9.00 expecting QNCX to rise to within 12 months (a possible 386.49% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Quince Therapeutics (NASDAQ:QNCX) was provided by Brookline Capital, and Quince Therapeutics initiated their buy rating.

There is no last upgrade for Quince Therapeutics

There is no last downgrade for Quince Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quince Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quince Therapeutics was filed on December 18, 2024 so you should expect the next rating to be made available sometime around December 18, 2025.

While ratings are subjective and will change, the latest Quince Therapeutics (QNCX) rating was a initiated with a price target of $0.00 to $9.00. The current price Quince Therapeutics (QNCX) is trading at is $1.85, which is within the analyst’s predicted range.